Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study
Abstract Background Polymyxin B is the first-line therapy for Carbapenem-resistant organism (CRO) nosocomial pneumonia. However, clinical data for its pharmacokinetic/pharmacodynamic (PK/PD) relationship are limited. This study aimed to investigate the relationship between polymyxin B exposure and e...
Main Authors: | Tiantian Tang, Ying Li, Ping Xu, Yanjun Zhong, Min Yang, Wanjun Ma, Daxiong Xiang, Bikui Zhang, Yangang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Critical Care |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13054-023-04448-z |
Similar Items
-
Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
by: Yiying Cai, et al.
Published: (2020-07-01) -
Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
by: Zhenwei Yu, et al.
Published: (2022-12-01) -
Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>: A Propensity Score-Matched Cohort Study
by: Lei Zha, et al.
Published: (2023-01-01) -
Outbreak of carbapenem-resistant Klebsiella pneumoniae: two-year epidemiologic follow-up in a tertiary hospital
by: Graziella Hanna Pereira, et al.
Published: (2013-02-01) -
Outbreak of carbapenem-resistant Klebsiella pneumoniae: two-year epidemiologic follow-up in a tertiary hospital
by: Graziella Hanna Pereira, et al.
Published: (2013-02-01)